Supplementary materials and methods (1) Estimation of the pre-treatment frequency of infected cells
To estimate the pre-treatment frequency of HCV infected hepatocytes in each patient, we used the following previously determined relationship with measured serum viral load of a patient (1). Let N denote the total number of hepatocytes in the liver, f the pre-treatment frequency of infected cells, hence, I=fN, denotes the number of infected hepatocytes in the liver. We assume that each infected hepatocyte has an average intracellular HCV RNA content of H and that viral RNA is packaged and exported from infected cells at a rate ρ. Denoting the physiological clearance rate of extracellular virus by cp, the serum viral load of a patient, V, can be estimated by
Hereby, γ denotes a scaling factor to account for the fact that V is measured per ml of serum, while ρfNH/cp defines the total number of virions in the human body. As the total extracellular fluid volume for a 70kg individual is estimated to be ~15L (2), we define γ dependent on the weight, w, of the patient
The correction factor of 0.95 was chosen as we observed previously that estimates of the viral load based on the measured frequency of infected cells in liver biopsy samples and their amount of intracellular HCV RNA was usually 0.3 logs (or 5%) of the actually measured viral load (1). With Eq.S1
and Eq.S2, the pre-treatment frequency of infected cells can be formulated as (3), respectively, and we varied both of them uniformly within their confidence intervals. In addition, the total number of hepatocytes, N, is assumed to be between ~10 11 -2x10 11 Using these parameterizations, the pre-treatment frequency of infected hepatocytes for an individual of ~70kg based on the serum viral load is shown in Supplementary Table A and Supplementary Fig AB. Due to the uncertainty in the upper bound of these estimates (especially in viral load > 6 log IU/ml), i.e. the assumed exponential relationship for H(V) might be underestimating the true intracellular viral RNA content for these viral loads (6) , only the minimum estimates were used.
Individual estimates for each patient are shown in Table 2 .
(2) Description of the nonlinear mixed effect models.
Nonlinear mixed effect models (or population approach) were first developed to study the pharmacokinetics (PK) of drugs (7). This method allows a description of population characteristics (mean parameters) as well as the inter-individual variability (IIV) (8) . In this method, a function f describing the variables being modeled, e.g., the viral load or drug concentration, depends nonlinearly on θi, a vector of the p parameters of subject i. A vector ξi representing the times at which samples are collected from subject i, ξi = (ti1; ti2;…; tin), is also considered. The statistical model for subject i is then given by:
where yi is a vector with ni observations of subject i, with i varying from 1 to N, i is the vector of the residual errors which is the part of the observations unexplained by the model f. It is assumed that the errors i are independent from one observation to another and that their distribution is Gaussian i ~ N(0; Ini), where Ini is an identity matrix of dimension ni. a is a parameter characterizing the error model variance.
In nonlinear mixed effect models, the model f is common to all the subjects, but the vector of parameters θi for subject i may vary from one subject to another. The inter-individual variability is modeled with the vector of random effect parameters θi. The vector of parameters θi for the subject i can then be expressed as a second-level model which links with the function g, the vector of fixed effect parameters  common for all subject and the vector of random effects ηi specific for subject i: θi = g(;ηi).
The vector of random effect is assumed to follow a Gaussian distribution ηi ~ N(0; Ω), ηi and i are assumed to be independent for subject i and ηi |i is assumed independent from one subject to another.
Ω is the matrix of random effect variance. Here, the function g is an exponential model. The vector of parameters is hence written as = .
The residual error measures the difference between predictions and observations. The model used was:
. y is the observed response, f is the model function, a is the additive error term, and the error  is normally distributed following HCV RNA data including the first viral load below the limit of quantification (<15 IU/ml) or below the limit of detection was used for model fits, using a population approach, whereas the subsequent observations were truncated. In order to accurately estimate the model parameters we excluded two subjects (R1 and H10) with less than 2 samples above the limit of quantification. The viral clearance rate constant was fixed to c=6/day ( Table 2 ). The population parameters: baseline viral load (V0), ε and  and their inter-individual variability (IIV) estimates were obtained using a maximum-likelihood method implemented in MONOLIX version 4.3.2 (Lixoft, Orsay, France), which uses the stochastic approximation expectation-approximation (SAEM) algorithm (9) to estimate population parameters.
The model was fit to log10 viral load. HCV genotype and patient type (treatment naïve vs. nonresponder) were included as covariates in the model to study their effect on the parameters. Individual parameters were estimated using the empirical Bayes method (10). The BIC (11) was used to compare various models. Further analysis predicted that the total mean time to reach a definition of cure defined as not only <1 virus copy in the entire extracellular fluid, but also <1 infected hepatocyte was 8.6 weeks [95%CI: 7.7 to 9.6 weeks]. Using time to this dual endpoint as the threshold to achieve cure predicts that, 20 (37%) subjects reached cure after 6 weeks of therapy, 4 (7%) subject after 8 weeks, 19 (35%) subjects after 10 weeks, 3 (6%) subject after 12 weeks, and 8 (15%) subjects with more than 12 weeks of therapy (Fig. SB) . Restricting the analysis to patients with HCV genotype-1 (n=50) did not change the pattern of results. However, since all subjects achieved SVR but one relapser (L1, Table 2 and Fig. 2 ), the prediction of more than 12 weeks of treatment to achieve <1 infected cell in 7 individuals (S3, D5, D11, D14, L5, L13 and L18 - Table 2 ) who achieved SVR with 12-week therapy is an overestimate. Table A 
Supplementary

